{"id":846036,"date":"2026-06-05T11:45:47","date_gmt":"2026-06-05T11:45:47","guid":{"rendered":"https:\/\/www.europesays.com\/us\/846036\/"},"modified":"2026-06-05T11:45:47","modified_gmt":"2026-06-05T11:45:47","slug":"revolution-medicines-pancreatic-cancer-drug-proving-hard-to-get","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/846036\/","title":{"rendered":"Revolution Medicines’ pancreatic cancer drug proving hard to get"},"content":{"rendered":"

Amy Johnston is distraught and readily admits that she is \u201cgrasping at straws.\u201d<\/p>\n

Diagnosed last year with pancreatic cancer, she has had chemotherapy and surgery and is now enrolled in a clinical trial hoping to delay progression of the disease. By the end of this month, she expects to know if the treatment is working; if it\u2019s doesn\u2019t, she and her physician plan to seek access to\u00a0another drug that, while still technically experimental, is causing a sensation<\/a>.<\/p>\n

The drug, called daraxonrasib<\/a> and developed by Revolution Medicines, nearly doubled overall survival time in pancreatic cancer patients in a clinical trial. It is now being offered through an expanded access program,<\/a> which allows critically ill people to receive an experimental medicine outside of such a study.<\/p>\n

But for Johnston and other patients, the excitement has come with anxiety. On one hand, there is optimism that the treatment \u2014\u00a0expected to be approved as a second-line therapy \u2014\u00a0can prolong their lives. Yet there is so much interest and demand that patients are trepidatious about when they might get the drug or if there will be enough to go around.<\/p>\n

\u201cThis is such a small company, and I worry their production is not able to keep up with the need,\u201d said Johnston, a 35-year-old office administrator and mother of three young children who lives in Gilbertsville, Pa. \u201cWho receives it first? Will it be for those who the drug is the last resort? It\u2019s a good idea, but how early can you get it to people?<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Amy Johnston is distraught and readily admits that she is \u201cgrasping at straws.\u201d Diagnosed last year with pancreatic…\n","protected":false},"author":3,"featured_media":846037,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[11],"tags":[150,235,210,152,153,881,154,67,132,68],"class_list":["post-846036","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-biotechnology","tag-cancer","tag-health","tag-pharmaceuticals","tag-policy","tag-public-health","tag-stat","tag-united-states","tag-unitedstates","tag-us"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116697336789410535","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/846036","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=846036"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/846036\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/846037"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=846036"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=846036"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=846036"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}